<DOC>
	<DOCNO>NCT01188668</DOCNO>
	<brief_summary>The goal study evaluate effect multiple dos Desvenlafaxine Sustained Release ( SR ) pharmacokinetics Aripiprazole coadministered healthy adult subject . This study also evaluate safety tolerability Desvenlafaxine SR Aripiprazole coadministered healthy adult subject .</brief_summary>
	<brief_title>Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release ( DVS SR ) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year Body Mass Index ( BMI ) 17.5 30.5 kg/m2 total body weight &gt; 50 kg ( 110 lb ) Nonsmoker smoker few 5 cigarette per day determine history An informed consent document sign date subject History significant blood , kidney , endocrine , lung , gastrointestinal , heart , liver , psychiatric , neurologic , allergic disease History seizure disorder Presence history glaucoma increase intraocular pressure Allergy unable tolerate aripiprazole , desvenlafaxine , venlafaxine History substance abuse within 1 year study A positive urine drug screen Treatment investigational drug within 30 day Consumption grapefruit grapefruit relate citrus fruit 12 lead ECG demonstrate QTc &gt; 450 msec screen Pregnant nursing female Use prescription nonprescription drug dietary supplement History sensitivity heparin heparin induce thrombocytopenia Severe acute chronic medical psychiatric condition laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>genetic testing</keyword>
	<keyword>CYP 2D6 CYP 3A4</keyword>
</DOC>